Public Joint-Stock Company "Human Stem Cells Institute" (MISX:ISKJ) announced a private placement of 10,000,000 common shares with Limited Liability Company "IceGen 2" on June 23, 2020. The company will issue shares at a price to be determined by the board of directors of the company based on its market value and cannot be lower than the par value of shares. Post-closing, the authorized capital of company will increase from RUB 7,500,000 to RUB 8,500,000. The transaction has been approved in the annual general meeting of shareholders of the company